Indeed, while the anti-CD20 antibody is now regularly employed as a hematological cancer therapeutic and represents a breakthrough in the treatment of B cell malignancies12–14, these anti-CD20-specific antibodies, as well as CD52 specific alemtuzumab, Her2/neu-specific trastuzumab, EGRF-specific cetiuximab and anti-GD-2 antibodies are all under investigation in clinical trials to target depletion of both cancer and immune cells10, 15–17. The gene discussed is ERBB2; the disease is cancer.